A novel antigen biomarker for detection of high-level of Loa loa microfilaremia
This Ll-Bhp-1 antigen assay is specific for loiasis, and highly sensitive for identifying people with high L. loa microfilarial counts who are at increased risk for serious adverse events after ivermectin treatment. L. loa antigen detection has the potential to facilitate loiasis mapping efforts and programs to eliminate lymphatic filariasis and onchocerciasis in Central Africa.
Authors
- Joseph Kamgno (ORCID: https://orcid.org/0000-0003-1572-3490)
- Peter Fischer (ORCID: https://orcid.org/0000-0003-4558-3417)
- Bruce A. Rosa (ORCID: https://orcid.org/0000-0002-6820-446X)
- Philip J. Budge (ORCID: https://orcid.org/0000-0002-0069-2372)
- Gary J. Weil (ORCID: https://orcid.org/0000-0002-6336-3824)
- Sarah E. Greene (ORCID: https://orcid.org/0000-0001-6561-2698)
- Samuel Wanji (ORCID: https://orcid.org/0000-0003-0022-8366)
- Makedonka Mitreva (ORCID: https://orcid.org/0000-0001-9572-3436)
- John Martin (ORCID: https://orcid.org/0000-0003-1235-5952)
- Kerstin Fischer (ORCID: https://orcid.org/0000-0002-2963-1303)
- Yuefang Huang (ORCID: https://orcid.org/0000-0003-2742-3583)
- D. A. Yates
Institutions
- James S. McDonnell Foundation (US)
- Université de Yaoundé I (CM)
- University of Buea (CM)
- Washington University in St. Louis (US)
Publication Details
- Journal
- PLoS neglected tropical diseases
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1371/journal.pntd.0012461
- Citations
- 3
- Primary Topic
- Parasitic Diseases Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Bill and Melinda Gates Foundation
- Foundation for Barnes-Jewish Hospital
- European and Developing Countries Clinical Trials Partnership